Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Norwegian Cruise Line Holdings Ltd — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.04 (market cap $2.81B), while Norwegian Cruise Line Holdings Ltd trades at $14.89 (market cap $6.83B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 2.4× Dyne Therapeutics Inc. Common Stock's market cap, and Norwegian Cruise Line Holdings Ltd is more actively traded (16,506,314 versus 2,195,902). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Norwegian Cruise Line Holdings Ltd for 69 Days on average.
| DYN | NCLH | |
|---|---|---|
Market Cap | $2.81B | $6.83B |
Volume | 2,195,902 | 16,506,314 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $25.02 |
52-Week Low | $14.60 | $14.12 |
Typical Hold Time | 0 Days | 69 Days |
Enterprise Value | $2.13B | $21.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
NCLH trades at $15.32, down 0.2% on the day, with a neutral technical signal and bearish moving averages. The company reported Q2 2026 EPS of $0.48, beating expectations, and expects Q3 results to exceed guidance. Revenue grew to $9.83B in 2025, with a net income margin of 4.3%. Valuation ratios appear attractive with a P/E of 9.28 and P/S of 0.74. Recent news highlights pricing strategies to boost advance bookings and a $950M senior notes offering.
The outlook is mixed: strong earnings beats and analyst buy consensus (51.35%) support upside to the $20.86 price target, but high debt levels and yield pressure pose risks. Investors should weigh solid fundamentals against industry headwinds and financial leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
